Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.

by Annie Y Chen, Marija Zeremski, Ranjit Chauhan, Ira M Jacobson, Andrew H Talal, Tomasz I Michalak
Published 2013-01-01

Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment

by Chenyang Zhan, Vinay Prabhu, Stella K. Kang, Clayton Li, Yuli Zhu, Sooah Kim, Sonja Olsen, Ira M. Jacobson, Nabil N. Dagher, Brendan Carney, Ryan M. Hickey, Bedros Taslakian
Published 2021-05-01

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

by David E. Bernstein, Albert Tran, Paul Martin, Kris V. Kowdley, Marc Bourliere, Mark S. Sulkowski, Paul J. Pockros, Boris Renjifo, Deli Wang, Diana L. Shuster, Daniel E. Cohen, Ira M. Jacobson
Published 2019-02-01

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

by Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann Tigges, Inge Dierynck, Joan Spanks, Jennifer Dorrian, Min Jiang, Bambang Adiwijaya, Anne Ghys, Maria Beumont, Robert S Kauffman, Nathalie Adda, Ira M Jacobson, Kenneth E Sherman, Stefan Zeuzem, Ann D Kwong, Gaston Picchio
Published 2012-01-01

P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies

by Stuart K. Roberts, Curtis L. Cooper, Eric Lawitz, K. Rajender Reddy, Alex J. Thompson, Stefan Zeuzem, Ira M. Jacobson, Peter Ruane, Robert H. Hyland, Luisa M. Stamm, Lingling Han, Diana M. Brainard, Norbert Bräu, Tarik Asselah, Bernard E. Willems, Steven Flamm, Marc Bourlière, Graham R. Foster, Edward J. Gane, Michael Manns, Stuart C. Gordon, Kris Kowdley
Published 2017-08-01